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Metals and metal compounds are part of our environment. Several metals are essential for physiological functions (e.g., zinc
or magnesium); while the beneﬁcial eﬀects of others are uncertain (e.g., manganese), some metals are proven to be toxic
(e.g., mercury, lead). Additionally there are organic metal compounds; some of them are extremely toxic (e.g., trimethyltin,
methylmercury), but there is very little knowledge available how they are handled by organisms. Scientiﬁc evidence indicates
that long-term exposure to (some) metallic compounds induces diﬀerent forms of cancer, including breast cancer. On the other
side, several metal compounds have clinical use in treating life-threatening diseases such as cancer. In this paper we discuss the
recent literature that shows a correlation between metal exposure and breast cancer.
1.Introduction
According to the World Health Organization, breast cancer
accounts for 16% of all types of cancer deaths globally (total
deathsofcancer7,600,000,totalbreastcancerdeaths460,000
[1]).Itisthemostcommonsolidtumordiagnosedinwomen
[2]. Although the incidence of breast cancer increases with
age [3], certain lifestyle and environmental factors play an
important role on breast cancer risk [4]. Such risk factors
include the genetic background and environmental factors.
For example, women who have inherited mutations in the
BRCA1 or BRCA2 genes have substantially elevated risks of
breast cancer [5].
Also an elevated lifetime estrogen exposure might be
major risk factor for breast cancer [6]. However, the
activation of estrogen receptors alone is not suﬃcient for the
developmentofbreastcancer[7]indicatingthatotherfactors
play an important role in carcinogenesis. The underlining
mechanism could rely on the ability of estrogen and estrogen
metabolites to generate reactive oxygen species which induce
DNA synthesis, increased phosphorylation of kinases, and
activation of transcription factors, such as AP-1, NRF1,
E2F, NF-κB, and CREB responsive to either oxidants (e.g.,
toxins, including metal compounds) or estrogen. Therefore,
the genomic instability increases while the activation of
transcription factors plays an important role in cell transfor-
mation, cell cycle, migration, and invasion [7].
Environmental factors also play a decisive role in breast
carcinogenesis together with life-long dietary habits [4].
More and more evidence underlines that external factors
are involved in the development of breast cancer: nutrition
(obesity and alcohol consumption), smoking, and exposure
to carcinogens (e.g., metal compounds) [4]. Multiple reports
show that metallic compounds could function as estrogen
disruptors [8], while other studies underline the connection
between the exposure to metals or metal compounds and
breast cancer risk [2, 9, 10].
The present paper discusses emerging data in support
of the role of metal compounds in the development of
breast cancer. It is envisioned that estrogen-induced metal-
mediated signaling is a key complementary mechanism
that drives the carcinogenesis process. On the other hand
it also highlighted the beneﬁcial eﬀects of metal-derived
compounds, which are used for the treatment of cancer
(e.g., platinum compounds have been a breakthrough for the
treatment of breast cancer) [11].
Inthefollowingsectionstheassociationofspeciﬁcmetals
(and their compounds) in regard to their eﬀects in inducing
b r e a s tc a n c e ra r ed i s c u s s e da sw e l la sb e n e ﬁ c i a le ﬀects of
metals in treating the same cancer.2 Journal of Toxicology
2.Epidemiologic StudiesIllustrating
the Effects of Multiple Metals
A large number of epidemiologic studies associate potential
risk factors forcancerwith metals such as selenium (Se), zinc
(Zn), arsenic (As), cadmium (Cd), and nickel (Ni), which
are found naturally in the environment. Human exposure
to these metals results from air, drinking water, and food
[12, 13]. Other studies demonstrated that age-corrected
breast cancer mortalities in diﬀerent countries are inversely
correlated with the dietary intake of Se and directly with the
estimated intake of Cd, Zn, and chromium (Cr), suggesting
that the anticarcinogenic properties of Se are counteracted
by these elements [14]. As mentioned before, these metals
can mimic the action of estrogen; the estrogenicity of various
heavy metals was described in [15], for example, bis(tri-n-
butyltin)>cadmiumchloride>antimonychloride>barium
chloride =chromiumchloride>lithiumhydroxide>sodium
selenite = lead acetate > stannous chloride.
While an association between exposure to metals and
the risk of the lung, breast, colorectum, prostate, urinary
bladder, and stomach cancers is discussed, it was demon-
strated that breast cancer patients have abnormal levels
of copper (Cu), Zn, Se, and Cd [16], Interestingly, other
evidence shows an inverse association between Se exposure
and prostate cancer and lung cancer risk. There is also some
evidence for an inverse association between Zn and breast
cancer, while there is no association between exposure to Se
and the risk of breast, colorectal, and stomach cancer and
between Zn and the risk to develop prostate cancer [12].
Nevertheless, positive associations of breast cancer with Zn,
iron, and calcium, but little association with Se, have been
reported in [17].
In particular, a study of [16] showed that the genetic
instability found in stage I breast cancer patients (frequency
of micronucleated lymphocytes) was related with the blood
levels of Cu, Zn, Se, and Cd. The authors found that the
level of Cu, Zn, and Se was signiﬁcantly lower in breast
cancer patients, as compared to controls while the level of
Cd was signiﬁcantly higher in these patients. In breast can-
cer patients, the frequency of micronucleated lymphocytes
showed complex associations with diﬀerent concentrations
of these elements. High Cd, low Zn, low Se, and both high
and low Cu levels increased the micronucleus formation in
lymphocytes. A similar correlation was found in the control
group only in relation to high Se and Cd levels [16].
3. Arsenic
Arsenic (As) exposure constitutes one of the most wide-
spread environmental carcinogens and is associated with
increased risk of diﬀerent types of cancers [18–20]. Arsenites
are found in drinking water and are used in wood preserva-
tives, insecticides, and herbicides. Epidemiological evidence
has associated exposure to As in drinking water with an
increased incidence of human cancers in the skin, bladder,
liver, kidney, and lung [21, 22], and low concentrations
of As2O3 induce carcinogenesis after long-term exposure
[23].
Nonetheless, arsenic trioxide (As2O3)i sa l s oac o m -
ponent of traditional Chinese medicine [24]. In clinics
it is successfully used to treat hematologic malignancies.
However, the antitumor eﬀects could not be replicated for
solid tumors [11, 23, 25], although in vitro As2O3 induces
apoptosis in other solid cancer cell lines including breast
cancer cells [19, 20, 23, 26]. In either application, the precise
molecular mechanisms through which As2O3 induces cell
cycle arrest and apoptosis in solid tumors have not been fully
understood [24]. Hopefully, new insights into how As2O3
binds to speciﬁc receptors and how they trigger signaling
pathways might facilitate As2O3-based anticancer strategies
and/or combination therapies in order to treat solid tumors
[18, 24].
A large body of evidence indicates that arsenic com-
pounds induce cell death in breast cancer cells and the
induction of this eﬀect is a possible endorsement for the
treatment of breast cancer. For example, sodium arsenite
mimics the eﬀects of estradiol and induces cell proliferation
in the estrogen-responsive breast cancer cell line MCF-7
while the S-phase recruitment was increased [22]. Interest-
ingly, regarding the cell proliferation, a paradox eﬀect was
observed: lower concentrations (<5μM) of sodium arsen-
ite induced cell proliferation while higher concentrations
(>5μM)orlongertreatmentperiodsinducedapoptosis [21].
In addition, As also inﬂuences the enzymes participating in
the folate cycle [21].
Other studies indicate that arsenite, in environmental
relevant concentrations (5μM/0.65mg/L), is able to induce
both replication-dependent DNA double-strand breaks and
homologousrecombination.Double-strandbreakformation
was replication dependent and probably the result of conver-
sion of a DNA single-strand break into double-strand breaks
[18]. In addition, low arsenite concentrations (0.5–5μM)
induce ROS production and ROS-related depolarization of
the mitochondrial membrane, suggesting that mitochondria
play an important role in the oxidative eﬀects of As. In
addition, when ROS-mediated DNA damage is measured by
the presence of 8-OHdG DNA adducts in their nuclei, IκB
phosphorylation, NF-κB activation, and increases in c-Myc
and HO-1 protein levels were also observed. Therefore, these
factors might play a relevant role in the arsenite-induced
MCF-7 cell recruitment into the S-phase of the cell cycle
andcellproliferationobserved[22].Nonetheless,theauthors
conclude that arsenite activates several pathways involved in
MCF-7 cell proliferation, and, therefore, arsenite exposure
may pose a risk for breast cancer in exposed populations.
Additionally it was found that, in MCF-7 breast cancer
cells, As2O3 treatment changes the expression level of
several genes that are involved in cell cycle regulation,
signal transduction, and apoptosis. Important targets are
represented by proteins which inhibit the cell cycle like p21
and p27. Liu et al. [23] and Wang et al. [24] showed that
after 24h exposure to As2O3 (0.01–1μM) cell proliferation
signiﬁcantly increased and a progression from the G1 to
S/G2phasesoccurredinthenontumorigenicMCF10Abreast
epithelial cell line. Several cell-cycle-associated genes were
increased signiﬁcantly, for example, cell division cycle 6
(CDC6) and cyclin D1 (CCND1) which are closely relatedJournal of Toxicology 3
to cell cycle progression from G1 to S phase. In addition,
the production of ROS was elevated, while activation of
p38 MAPK, Akt, and ERK1/2 pathways was observed [23].
Arsenite also increases in MT1/2 and c-Myc protein levels
concentration dependently [21].
For treatment of solid tumors a novel nanoparticulate
formulation of As2O3 encapsulated in liposomal vesicles
named “nanobins” [NB(Ni, As)] was synthesized in order to
improve the therapeutic eﬃciency against breast carcinomas.
The NB (Ni, As) agent was less cytotoxic in vitro than
As2O3,a n din vivo NB (Ni, As) dramatically improved the
therapeutic eﬃcacy of As2O3. These eﬀects are possibly due
to a reduced plasma clearance, an enhanced tumor uptake,
and an induction of tumor cell apoptosis [25].
4. Cadmium
Cadmium (Cd) is a nonessential metal that is dispersed
throughouttheenvironment[27,28].Ithasbeencategorized
as a human carcinogen by the US Environmental Protection
Agency. Primary exposure sources include food and tobacco
smoke [8, 9, 27, 29]. Cadmium is a ubiquitous carcinogenic
pollutant and has multiple biological eﬀects, and exposure is
correlated with the occurrence of breast cancer in some US
regional case-control studies [2, 9, 10, 29].
Gallagher et al. [2]a sw e l la sM c E l r o ye ta l .[ 9]o b s e r - v e d
a signiﬁcant trend of an increased risk of breast cancer
by elevated urinary cadmium concentrations, but the
mechanisms of action of cadmium remain unclear
[8, 30]. Cd aﬀects multiple cellular processes, including
cell proliferation, diﬀerentiation, and apoptosis [8]. Cd
functions also as an endocrine disruptor, which stimulates
estrogen-receptor-α (ER-α) activity and promotes uterine
and mammary gland growth in and abolishes the cancer-
protecting eﬀects of Se in female inbred C3H mice carrying
murine mammary tumor virus [14].
Cd modulates gene expression, aﬀects the pattern of
transcriptional activity, and, therefore, changes intracellular
signals [31]. The modiﬁcation of gene expression in MCF7
cells is blocked by antiestrogens. Therefore, these eﬀects
could be mediated by ER-α [29, 30]. In estrogen-responsive
breast cancer cell lines, Cd stimulates proliferation and also
activates the estrogen receptor independent of estradiol [28–
30]. Cd activates extracellular regulated kinases, erk-1 and
-2 in both ER-positive and ER-negative human breast cancer
cells. High Cd concentrations from 50 to 500nM induced
a proliferative response SKBR3 cells, increased intracellular
cAMP levels. Cd treatment activates raf-1, mitogen-activated
protein kinase kinase, mek-1, extracellular signal-regulated
kinases, erk-1/2, ribosomal S6 kinase, rsk, and E-26 like
protein kinase, elk [28].
ER-α is required for both Cd-induced cell growth and
modulation of gene expression. ER-α translocates to the
nucleusinresponsetoCdexposureandpotentiatestheinter-
action between ER-α and c-Jun and enhances recruitment of
this transcription factor complex to the proximal promoters
ofcyclinD1andc-myc,increasingthemRNAexpression[8].
Additionally, Casano and colleagues in 2010 [31]c o n ﬁ r m e d
thattreatmentofbreastcancercellswith5μMCdCl2 induces
a diversiﬁed modulation of the transcription patterns of
p38, while [30] Sun and coworkers (2007) showed that
treatment of MCF-7 cells with Cd resulted in induction of
Hsp22. Cd increases breast cancer cell proliferation in vitro
by stimulating Akt, ERK1/2, and PDGFRα kinases activity
likely by activating c-fos, c-jun, and PDGFA by an ER-α-
dependent mechanism [32].
In chronic Cd exposure (over 40 weeks) of the human
breast epithelial cell line MCF-10A, secretion of matrix
metalloproteinase-9 increased, followed by a loss of con-
tact inhibition, increased colony formation, and increas-
ing invasion. Furthermore, inoculation of Cd-treated cells
into mice produced invasive, metastatic anaplastic carci-
noma. Additionally, breast stem cell markers CK5 and p63
were found overexpressed indicating persistent proliferation,
global DNA hypomethylation, and c-myc and k-ras overex-
pression [10]. Exposure of breast cancer cells to “subtoxic”
levelsofCdsigniﬁcantlyinhibitedtheangiogenicpotentialof
the breast cancer cell line, suggesting the possibility that Cd
might negatively regulate the production of proangiogenic
factors in breast cancer cells.
Interestingly, melatonin prevents the Cd-induced growth
of synchronized MCF7 breast cancer cells. Melatonin is a
speciﬁc inhibitor of Cd-induced ER-α-mediated transcrip-
tion,inhibitsMCF7cellgrowthinducedbyCd,andregulates
Cd-induced transcription in both ERE and AP1 pathways.
Overall, the antiestrogenic properties of melatonin might be
a valuable tool in breast cancer therapies [29].
Insummary,Cdmightexertaparadoxical eﬀectinbreast
cancer: on the one hand, it could promote carcinogenesis,
and, on the other hand, it could delay the onset of tumors by
inhibiting breast cancer cell-induced angiogenesis [27].
5. Gold
Gold nanoparticles (GNPs) are regarded as a possible
delivery vehicle for anticancer drugs and seem to have a great
potential to be used in clinics. In breast cancer MDA-MB-
231 cells the group of Jain [33] assessed the cellular uptake,
intracellular localization, and cytotoxicity of GNPs. When
GNPs were taken up, nanoparticles accumulated in cytoplas-
mic lysosomes. However, the GNP exposure did not increase
radiation-induced double-strand breaks formation and did
not inhibit DNA repair; but GNP chemosensitization was
observed in MDA-MB-231 cells treated with bleomycin [33].
For some time it was assumed that the GNPs are
but recent studies showed that this is not the case since
it was demonstrated that they cause oxidative stress and
even cell death, suggesting a possible biological mechanism
for sensitization [33]. Using syngeneic mouse and human
xenograft models of triple-negative breast cancer, Atkin-
son and his group demonstrated that local hyperthermia
generated by gold nanoshells plus radiation eliminates
radioresistant breast cancer stem cells [6]. Another study
by Day et al. [34] describes the possibility of using near-
infrared resonant gold-gold sulﬁde nanoparticles as dual
contrast and therapeutic agents for cancer management via
multiphoton microscopy followed by higher intensity pho-
toablation which can be utilized to visualize cancerous cells4 Journal of Toxicology
in vitro. When conjugated with anti-HER2 antibodies, these
nanoparticles speciﬁcally bind SK-BR-3 breast carcinoma
cells that overexpress the HER2 receptor, enabling the cells
to be imaged via multiphoton microscopy [34].
6.Platinum
Cisplatinisaﬁrstchoicechemotherapeuticdrugfordiﬀerent
types of cancer. Although there is increasing evidence that
breast cancers are sensitive to cisplatin, its clinical success
is often compromised due to dose-limiting nephrotoxicity
and the development of drug resistance. To overcome these
limitations, other platinum derivatives have been developed
for the treatment of breast cancer, and several of them
are still tested in clinical trials. In addition multiple drug
combination therapies (with include cisplatin) have been
employed [11, 35].
Multiple cellular eﬀects have been described for cisplatin
(for review see [11]). Recently it was demonstrated that
cisplatin increases the intracellular calcium concentration
dependently, and this increase of the intracellular calcium
signal is directly related to cytotoxicity [36]. This is in
agreement with similar results which were found earlier with
o t h e rc a n c e rc e l ll i n e s[ 37].
Regarding the molecular eﬀects triggered by cisplatin in
breast cancer cells, Wong et al. [35], showed that inhibition
of the mTOR, TGFbetaRI, NFκB, PI3K/AKT, and MAPK
pathwayssensitizedbasal-likeMDA-MB-468cellstocisplatin
treatment. Nevertheless, the combination of the mTOR
inhibitor rapamycin and cisplatin generated signiﬁcant drug
synergism in basal-like MDA-MB-468, MDA-MB-231, and
HCC1937 cells but not in luminal-like T47D or MCF-7
cells. The synergistic eﬀect of rapamycin plus cisplatin was
mediated by the induction of p73. The authors conclude that
a combination therapy with mTOR inhibitors and cisplatin
could be a useful therapeutic strategy for the treatment of
basal-like breast cancers.
A combination of gemcitabine and cisplatin was tested
in metastatic breast cancer and was successful in phase II
trials. This suggests that the combination of gemcitabine
and cisplatin is a safe and tolerable regimen and useful as
second-line combination for patients with anthracycline-
and taxane-pretreated MBC. It is mostly used as a salvage
regimen for progressive disease refractory to anthracyclines
and taxanes and when liver dysfunction secondary to liver
metastasis precludes these drugs [26, 38, 39].
It is also discussed whether a combination of cisplatin
and TRAIL has the potential to improve the therapeutic
outcome in triple-negative breast cancer (TNBC) patients.
This approach was tested in vitro on normal and triple-
negative breast cancer (TNBC cells) by Xu and coworkers
[40]. Indeed, this combination signiﬁcantly enhanced cell
death in TNBC cell lines and inhibited the expression of
EGFR, p63, survivin, Bcl-2, and Bcl-xL. Speciﬁc inhibition
of EGFR and/or p63 protein in TNBC cells was observed
while survivin played an important role in cisplatin plus
TRAIL-inducedapoptosisinTNBCcells.In vivo experiments
resulted in a signiﬁcant inhibition of CRL2335 xenograft
tumors compared to untreated control tumors [40].
It was speculated that whole body thermal therapy
would boost the eﬃcacy of oxaliplatin chemotherapy with
reduced toxicity. Indeed, elevating the temperature reduced
the IC50 of oxaliplatin in MTLn3 cells, while the cellular
uptake of platinum and platinum adducts increased. In
vivo, 50% of all oxaliplatin treated rats 24h before thermal
therapy were immunologically cured; in 11% their primary
tumor regressed but ultimately succumbed to metastases,
and 17% experienced a limited response with increased
survival. In uncured animals, the thermo-chemo-therapy
had a delayed incidence and slowed growth of metastases
[41].
The inhibitory activity of diﬀerent anticancer metal
complexes based on platinum, ruthenium, and gold metal
ions was evaluated on the zinc-ﬁnger protein PARP-1, either
puriﬁed or directly on protein extracts from human breast
cancer MCF7 cells. The results by Mendes and coworkers
[42] support a model whereby displacement of zinc from the
PARP-1 zinc ﬁnger by other metal ions leads to decreased
PARP-1 activity. In vitro combination on diﬀerent cancer cell
lines, including MCF7, showed synergistic eﬀects [42].
New platinum compounds are yet to be studied for
their potential to be used in anticancer treatment. A
series of seven platinum (II) cyclobutane-1,1-dicarboxylato
(cbdc) complexes {[Pt(cbdc)(L(n))(2)], 1–7},d e r i v e df r o m
carboplatin were studied for their in vitro cytotoxicity
activity against breast adenocarcinoma cells (MCF-7) and
were found to be cytotoxic [43]. Recently, Paraskar and
colleagues [44] reported a novel polymer, glucosamine-
functionalized polyisobutylene-maleic acid, where platinum
(Pt)canbecomplexedtothemonomericunits.Thiscomplex
self-assembles to a nanoparticle, which releases cisplatin in
a pH-dependent manner. Those nanoparticles are rapidly
internalized into the endolysosomal compartment of cancer
cells and exhibited a signiﬁcantly improved antitumor
eﬃcacy in breast cancers. Furthermore, the nanoparticle
treatment resulted in a reduced systemic and nephrotoxicity,
which was due to a decreased distribution of platinum
to the kidney [44]. The in vitro antitumor activity of
the [Pt(ox)(L(n))(2)] (1–7) and [Pd(ox)(L(n))(2)] (8–14)
oxalato complexes involving N6-benzyl-9-isopropyladenine-
based N-donor carrier ligands (L(n)) against breast adeno-
carcinoma (MCF7) were studied by Paraskar and coworkers
[44].Thisgroupfoundthetestedcomplexestobemorecyto-
toxic compared to cisplatin, but they were non-hepatotoxic
[44].
In MCF-7 cells [Pt(O,O -acac)(γ-acac)(DMS)] had toxic
eﬀects at high concentrations, while subcytotoxic con-
centrations induced anoikis and decreased cell migration.
This compound altered [Ca2+]i homeostasis and triggered
apoptosis. When cells were stimulated with ATP, the changes
in Ca2+ levels caused by purinergic stimulation were altered
due to decreased PMCA activity and due to the closure of
Ca2+ channels opened by purinergic receptors. Conversely,
[Pt(O,O -acac)(γ-acac)(DMS)] did not aﬀect the store-
operated Ca2+ channels opened by thapsigargin or by ATP,
but it provoked the activation of PKC-α and the production
of ROS that were responsible for the Ca2+ permeability and
PMCA activity decrease [45].Journal of Toxicology 5
7.Lead
Breast cancer incidence in women has been related to
industrialization suggesting that the associated widespread
contamination of the soil, air, and the water by lead (Pb)
and other industrial metals is a major risk factor. Due to
its wide use, Pb is of particular concern. In levels as low as
0.5ppmPb(indrinkingwater),itpromotesthedevelopment
of mammary murine tumors in virus-infected female C3H
mice [46]. It also accelerates tumor growth rates. Higher
levels of Pb were found in blood and head hair samples
of newly diagnosed patients with breast cancer, all with
an inﬁltrating ductal carcinoma [46]. The Pb levels in the
hair samples were directly correlated with the volumes of
the tumors [46]. The same researchers also found evidence
that Pb and other metals also interact with iodine, a vitally
important essential trace element that most likely protects
against breast cancer development [46].
On the other side, some new metal-organic lead struc-
tures have been developed over the last years, which actually
exhibit cytostatic properties. However, the eﬃciency of such
chemotherapeutics in the treatment of tumors might be
limited by their low therapeutic index due to their short
half-life, lack of tumor selectivity, and associated side eﬀects
[46].
8. Cymantrene-PeptideConjugates
Cymantrene (CpMn(CO3)) is a robust organometallic
group, which is stable in air and water. In experiments done
by Splith and coworkers [47], cymantrene derivatives were
attached to the cell-penetrating peptide sC18 which acted as
a transporter for the metal moiety. This group characterized
the conjugates for their cytotoxic activity on human breast
adenocarcinoma cells (MCF-7) and human colon carcinoma
cells (HT-29). These researchers found that bioconjugates
bearing two cymantrene groups were more active than the
monofunctionalized ones and that, by the introduction of a
cathepsin B cleavage site next to the organometallic group,
the biologic activity was increased [47].
9.Selenium
T h er o l eo fS ea sap o t e n t i a lc a n c e rc h e m o p r e v e n t i v ea n d
chemotherapeuticagenthasbeensupportedbyepidemiolog-
ical, preclinical, and clinical studies [48–50]. Se levels in hair
and blood were inversely correlated with tumor volumes,
which are consistent with the antiproliferative eﬀects of Se
[46].
While cell apoptosis is a critical mechanism mediating
theanticanceractivityof Se,theunderlying molecularmech-
anisms still remain elusive [48]. The anticancer properties of
Se might be due to the fact that it partially protects against
oxidative stress [51]. The same group also assessed whether
supplementation of BRCA1 mutation carriers with Se has
ab e n e ﬁ c i a le ﬀect to oxidative stress/DNA damage since
Se supplementation in patients may result in reduction of
oxidative DNA damage. They found that BRCA1 deﬁciency
contributesto8-oxodGaccumulationincellularDNA,which
in turn is a factor responsible for cancer development in
women [51].
Se compounds modify gene expression. When breast
epithelial cells (MCF-10A) were exposed to 100nM sodium
Se or high-Se serum, the expression of 560 genes including
60 associated with the cell cycle were aﬀected. The group of
Hawkes et al. [52] describes that selenoprotein W (SEPW1)
was the only selenoprotein increased by both sodium
selenite (speciﬁc) and high-Se serum (physiologic). SEPW1
small interfering RNA inhibited G1-phase progression and
increased G1-phase gene transcripts while decreasing S-
phase and G2/M phase gene transcripts, indicating that the
cell cycle was interrupted at the G1/S transition. SEPW1
mRNA levels were maximal during G1 phase, dropped after
the G1/S transition, and increased again after G2/M phase.
SEPW1-underexpressing prostate cells had increased mRNA
for BCL2, which can induce a G1 arrest and decreased
mRNA for RBBP8 and KPNA2, which modulate the Rb/p53
checkpoint pathway. Altogether, these results suggest that
SEPW1 and the G1/S transition are physiological targets of
Se in breast and prostate epithelial cells [52].
Selenocysteine (SeC), a naturally occurring selenoamino
acid, induces a caspase-independent apoptosis in MCF-7
breast carcinoma cells, accompanied by poly (ADP-ribose)
polymerase (PARP) cleavage, caspase activation, DNA frag-
mentation, phosphatidylserine exposure, and nuclear con-
densation. Moreover, SeC induced a loss of the mitochon-
drial membrane potential (Delta Psi (m)) involving the
expression and phosphorylation of Bcl-2 family members.
Loss of Delta Psi (m) induced the mitochondrial release
of cytochrome C and apoptosis-inducing factor followed
by chromatin condensation and DNA fragmentation. MCF-
7 cells exposed to SeC showed an increase in total p53
andphosphorylatedp53prior tomitochondrial dysfunction.
Silencing and attenuating of p53 activation partially sup-
pressedSeC-inducedcellapoptosis.Furthermore,generation
of reactive oxygen species and the induction of DNA strand
breaks were found. Therefore, SeC could be a promising
anticancer compound, which induces MCF-7 cell apoptosis
by activating the ROS-mediated mitochondrial pathway and
p53 phosphorylation [48].
Semightbebeneﬁcialincombinationwithotherdrugsin
adjuvant therapy. Therefore, the combination of anticancer
drugswithSecombinationswasinvestigated.Lietal.[53,54]
investigated the therapeutic eﬀect of methylselenocysteine
(MSC) combined with tamoxifen in MCF-7 breast cancer
xenograft. Indeed, treatment with tamoxifen together with
MSC synergistically inhibited tumor growth compared to
MSC alone and tamoxifen alone. MSC alone or MSC +
tamoxifen signiﬁcantly reduced ERα, PR and cyclin D1, Ki67
index, and microvessel density while increasing apoptosis
in tumor tissues. These ﬁndings demonstrate a synergistic
growth inhibition of ERα-positive breast cancer xenografts
for a combination of tamoxifen with organic selenium
compounds [53, 54].
The group of Li showed that combining doxorubicin
with selenium resulted in an enhancement of apoptosis in
MCF-7 human breast cancer cells [55, 56]. They found that
mitochondrial activation of caspase-9 is in part responsible6 Journal of Toxicology
for the synergy; while the death receptor pathway was
involved in the activation of caspase-8. On the other
hand, Se increased the expression of FADD, which is
responsible for recruitment of caspase-8 to the Fas oligomer.
Therefore, doxorubicin and selenium cooperatively activate
Fas signaling by targeting key regulatory steps [56].
Se was capable of depressing doxorubicin-induced Akt
phosphorylation, important in mediating the synergy
between Se and doxorubicin. Se reduced the abundance
of phospho-GSK3β induced by doxorubicin, whereas
chemical inhibition of GSK3β activity muted the apoptotic
response to the Se/doxorubicin combination. Se increased
the transactivation activity of FOXO3A [55].
10. Conclusion
Metals and metal compounds interfere with breast cancer
in multiple ways. On the one side, they are an important
risk factor for the development of breast cancer, while on
the other side their cytotoxicity might have also beneﬁcial
eﬀectsininducingapoptosisandcytotoxicityinbreastcancer
cells. To highlight this delicate balance and to understand
under which circumstances speciﬁcally cancer cells could be
targeted by metals and their compounds, further research is
needed.
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